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Summary
Background: Codeine containing preparations have the potential to cause harm and dependence. Recent UK regulatory 
changes to the pack-size and printed warnings have been instituted to reduce this potential. However, there is a reported 
increase in the misuse of codeine containing analgesics in countries where it is available over-the-counter. This is a 
challenge for pharmacies and pharmacists globally. Aim: To evaluate the perceptions of community pharmacists on the 
nature and management of Over-The-Counter (OTC) co-codamol (paracetamol and codeine combination preparations) 
misuse and abuse. Methods: A self-report, postal survey was developed and posted to 65 pharmacies in Cornwall and 
85 pharmacies in Devon (n=150) in the UK. Qualitative and quantitative data was analysed using descriptive statistics, 
hypothesis testing and thematic analysis. Results: Most pharmacists perceived their patients and community as having 
some challenges with the misuse of co-codamol. Pharmacists think that co-codamol is not harmful if used as indicated. 
The behaviours pharmacist associated with misuse were frequent to purchase and misinformation provided by the patient 
during consultation. Counselling and referral are the main interventions utilised by pharmacist in such circumstances. 
Pharmacists who have received training on co-codamol abuse know where to refer customers. Conclusions: Community 
pharmacists face a difficult challenge when suspecting misuse. However, pharmacists believe co-codamol abuse can be 
reduced by increasing the public’s awareness of the addictive potential of co-codamol.
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1. Introduction
The inappropriate use of OTC medications is 
referred to as misuse or abuse, due to their potential 
for addiction and dependency. Misuse and abuse can 
sometimes be misunderstood. For the purpose of this 
study, the definitions are adopted from EU commis-
sioned report [18] concerning codeine use, misuse 
and dependence. 
The definition of ‘misuse’ is: ‘The problematic 
consumption of codeine where risks and adverse con-
sequences outweigh the benefits, and which includes 
use of codeine with or without prescription, outside 
of acceptable medical practice or guidelines, for rec-
reational reasons, when self-medicating, with higher 
doses and for longer than advisable’ [3].
While the definition of ‘abuse’ is: ‘The use of 
drugs for nonmedical purposes is to experience their 
mind-altering effects, while “misuse” is applied to the 
use of a drug for legitimate medical purposes, but in 
an incorrect manner’ [1]. Both definitions imply rec-
reational use. Although these definitions are limited 
to codeine abuse and misuse, we use these definition 
as they are relevant to co-codamol use.
In the UK, there are three categories of licenced 
medicines for human use: 1. General Sales List (GSL) 
medicines, which can be readily purchased from re-
tailers, often containing a small quantity of analgesics 
and other preparations (not codeine-based). 2. Phar-
macy (P) medicines, which can be purchased OTC 
from a registered pharmacy where a registered phar-
macist oversees the sale (can be codeine-based). 3. 
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Prescription only medicines (POM), which must be 
supplied only against a valid prescription. Codeine 
preparations are sold OTC as P medicines or on a pre-
scription. Some examples of other commonly abused 
medications include benzodiazepines, z-drugs and 
opioid painkillers.
The misuse and abuse of OTC medicines is a 
worldwide problem [4, 17]; the five key groups of 
abuse range from laxatives, cough products, seda-
tive antihistamines, decongestants and codeine based 
analgesics [4, 9]. This is due to looser regulations, 
greater availability and self-medication [18, 16]. The 
misuse of codeine containing compound analgesics 
(normally in combination with ibuprofen or paraceta-
mol) is increasing in countries where it can be pur-
chased OTC [10]. Codeine containing analgesics are 
commonly associated with abuse and dependence due 
to the addictive and euphoric properties of codeine 
[18].
Associated with this euphoric effect is the con-
sequence of overconsumption of the compounded an-
algesic such as paracetamol. The potential health risk 
as a direct consequence of paracetamol overdose is 
hepatotoxicity [8] related to the chronic use of such 
products [6, 5, 8]. Similarly, when codeine is com-
bined with ibuprofen, overdose can result in nephro-
toxicity and gastric irritation. These health harms are 
amplified with dose escalation, which is commonly 
observed with chronic codeine misuse [16], because 
patients build tolerance to that dose of codeine and 
need a greater amount of codeine to generate the 
same euphoric effect, while sustaining damage from 
paracetamol and ibuprofen overdose. 
The initial use of such agents is often genuine 
and for appropriate indicated conditions. However, 
eventually it is taken for non-medical reasons and bor-
ders on dependency [8, 4, 15]. Some studies suggest 
that codeine dependence is subtly different to other 
opioid dependence. It requires different types of treat-
ment, abusers have different mental health problems, 
and they have more similarities to the general popula-
tion [11, 13]. Similarly, individuals mainly abusing 
codeine, labelled themselves as ‘social and economi-
cally active and different from illicit substance misus-
ers’ [4]. Additionally, individuals have described their 
codeine abuse as the ‘blurring’ between therapeutic 
and problematic use, whereby they think they are us-
ing it to relieve pain, while in fact they are using it to 
prevent opioid withdrawal symptoms [12].
Aims: The primary aim was to investigate the 
perceptions of community pharmacists on the misuse 
and abuse of OTC co-codamol (research question: 
what do community pharmacists think about co-co-
damol misuse and abuse?)
The secondary aim was to understand how com-
munity pharmacists suspect and manage co-codamol 
misuse or abuse (research question: how do commu-
nity pharmacists manage the phenomenon?)
2. Methods
The survey was developed from Carney et al’s 
[2] study. This study investigated views on regulatory 
changes, strategies used to identify misuse of codeine 
and how community pharmacists managed them.
To improve internal validity and reliability, the 
survey instrument was piloted, and cognitive testing 
(read aloud) was conducted on the final instrument. 
The feedback confirmed that the questions were in-
terpreted properly. Accompanying the survey was a 
participant information sheet, that highlighted the 
purpose of the study and invited participation. Tak-
ing part in the study was voluntary and anonymous. 
A pre-paid, self-addressed envelope was included 
to facilitate survey responses. Implied consent was 
assumed if surveys were returned. The duration of 
data collection was approximately 3 months from 
25/11/2016. 
Community pharmacies in Cornwall (n=65) and 
Devon (n=85) were surveyed, a sample representing 
approximately 60% of pharmacies in both counties. 
Devon had previously run a codeine awareness cam-
paign and Cornwall had not. Community pharmacies 
registered on NHS choices website were targeted. 
Registered and preregistration pharmacists were in-
vited to complete the questionnaire. 32 completed 
surveys (out of 150) were returned (response rate 
21%) from Devon (20) and Cornwall (12). 56% male 
and 44% females responded. 59% of respondents had 
eight years or more practice experience. 66% of these 
were full-time pharmacist.
Quantitative data were analysed using SPSS [7] 
software and qualitative data were analysed using 
NVivo [14] for thematic analysis.
2.1. Ethics statement
Prior to data collection, favourable ethical opin-
ion was received from the School of Pharmacy and 
Biomedical Sciences Research Ethics Committee on 
(Reference number: 2016.17 – 005, Date submitted: 
24-10-2016). This study is in line with declaration of 
Helsinki-ethical principles for medical research in-
volving human subjects.
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3. Results
88% of respondents reported knowing custom-
ers who regularly purchased co-codamol, with 44% 
purchasing co-codamol once or twice a week. 84% 
of respondents did not routinely recommend co-co-
damol for pain relief. Of these, 38% actively avoid-
ed recommending co-codamol for pain. 94% of all 
responders had offered alternatives to co-codamol 
during an OTC sale. 91% had denied prior sales of 
co-codamol to individual customers. 47% of respond-
ers believe that OTC use of co-codamol is harmful. 
Of these, 41% believed it encouraged the risk of ad-
dictive behaviour, 28% believed there was a risk of 
paracetamol overdose, a similar percentage believe 
there was a risk of endorsing abuse, 22% believed 
there was a risk of liver damage with chronic high 
paracetamol intake. However, 72% of responders in-
dicated that co-codamol should not be reclassified as 
a prescription only medicine (POM).
47% of respondents believed they served ‘low-
er-middle-class’ patients in their shop. 63% believed 
they knew where to refer customers for the treatment 
of co-codamol abuse. A Pearson chi-squared test sta-
tistic of 14.264 (p=0.002) rejects the null hypothesis 
that there is no association between perceived lower 
socio-economic status of patients and pharmacist’s 
knowledge of referral. 
Thematic analysis of the challenges associated 
with OTC co-codamol sale identified the following 
themes: 1. Patients, 2. Abuse, 3. Pharmacies. Patients: 
patients repeatedly requesting co-codamol, failed to 
understand the impact of their abuse on their health. 
Abuse: respondents reported patient abuse towards 
them including aggressiveness, defensiveness and 
abusive language and actions. Pharmacies: some re-
spondents would rather make a supply, even when 
they suspect abuse to secure revenues.
Thematic analysis of how patient’s health is safe-
guarded considering the above challenges revealed: 1. 
Use, 2. Patients, 3. Staff. Use: advice around safe use 
is given. Patients: patients are routinely questioned on 
their use of co-codamol. Staff: staff are locally made 
aware of frequent customers and the risk of abuse by 
individual patients.
66% of respondent had received no training on 
helping customers with co-codamol abuse. A Pearson 
chi-squared test statistic of 8.119 (p = 0.004) reject-
ed the null hypothesis that there was no association 
between pharmacists that had received training and 
pharmacists who knew where to refer customers for 
treatment. All respondents that received training with 
co-codamol abuse know where to refer customers for 
abuse support. Hence, Devon’s public health cam-
paign seems to have worked. 63% of all respondents 
would like to receive further training.
4. Discussion
Most of the responders were full-time phar-
macists working in communities they perceived as 
upper-middle-class areas. The obstacles they face 
included low-level co-codamol abuse. The Pearson 
chi-squared test suggests that poorer communities 
that face challenges of co-codamol abuse/misuse are 
doubly disadvantaged because the community phar-
macist lacks sufficient knowledge to be able to refer 
patients appropriately to address their addiction. Con-
versely, respondent working in upper-middle-class or 
middle-class backgrounds are more aware of appro-
priate referral pathways.
Pharmacist attempted to safeguard patients by 
asking questions and providing counselling for safe 
and appropriate use. They also shied away from rec-
ommending co-codamol and actively discourage its 
use. Many respondents had mixed opinions on the 
harm of OTC use of co-codamol. Most respondents 
concurred that OTC sale may risk ‘encouraging’ ad-
dictive behaviour. 
Regardless of these harms, it must be stressed 
that respondent-pharmacists do not believe that co-
codamol should be reclassified as prescription only, 
and many do not believe that the OTC use of co-
codamol is harmful. These recommendations are in 
line with the recent studies that suggest raising public 
awareness and education is needed as the first step 
in combating this problem. This education should not 
just be for co-codamol, but include all OTC codeine 
containing products. 
The main limitation of this study is the small 
sample size, where results are not generalisable. 
However, it provides a snapshot into current phar-
macy practice. There was a high completion rate for 
most questions, however, responder bias is possible. 
Further in-depth study is warranted given the global 
status of the opioid epidemic.
5. Conclusions
Community pharmacists face a difficult chal-
lenge in gaining the right balance of safe co-codamol 
use. Community pharmacists in Devon and Cornwall 
believe that abuse can be reduced by raising public 
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awareness and training pharmacist to spot the early 
signs of abuse. The magnitude of this challenge re-
mains small according to the respondent and pharma-
cists do not believe reclassification to POM is war-
ranted.
Co-codamol abuse is a complex and difficult 
challenge, which can be reduced via policy or public 
health promotion. Pharmacist believed that mandato-
ry counselling with co-codamol sale is essential. This 
could be achieved in several ways: having a desig-
nated ‘codeine’ staff, who is the single point of con-
tact for codeine sales and is themselves additionally 
trained for issues around addiction. There could be 
barcode scanned prompts at point of sale for essen-
tial counselling with each sale. Further, local training 
and awareness of pharmacists and their support staff 
via e-learning courses could further raise awareness 
amongst pharmacy professionals, including local 
signposts for addiction support counselling services.
Patients are made aware of the risk of addiction 
on the packaging: in the UK, printed warning for safe 
use of three days as a maximum and pack sizes are 
restricted to a maximum of three-day supply. Further 
OTC opioid-analgesics awareness programs could be 
run by the government.
Safety as a quality can be linked to medication 
and their safe use. Safety, can also be linked to patient 
qualities and characteristics, where some patients 
have a greater propensity for safety versus addiction. 
It is this second group, which benefits most from 
these safer modalities exercised by pharmacy.
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